Indivior (INDV) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
26 Feb, 2026Executive summary
Achieved record SUBLOCADE net revenue of $856M in 2025, up 13% year-over-year, with total net revenue of $1.24B, up 4% from 2024.
Adjusted EBITDA grew 20% year-over-year to $428M, with margin improvement of 5 percentage points.
Completed Phase I of the Action Agenda, simplifying the organization and focusing on growth and LAI penetration.
Launched a direct-to-consumer campaign in October 2025, significantly increasing SUBLOCADE awareness and engagement.
Paid $295M to resolve DOJ matter, eliminating a major liability, and authorized a new $400M share repurchase program.
Financial highlights
Q4 2025 net revenue was $358M, up 20% year-over-year; SUBLOCADE net revenue was $252M, up 30% year-over-year.
Full-year net revenue was $1.24B, up 4%; adjusted EBITDA was $428M, up 20% year-over-year.
Q4 adjusted EBITDA rose 91% year-over-year to $142M, with margin at 40%.
FY 2025 gross profit was $994M (80% margin); non-GAAP gross profit was $1,040M (84% margin).
Net income for FY 2025 was $210M; non-GAAP net income was $320M, up 33% year-over-year.
Outlook and guidance
2026 total net revenue guidance: $1.125B–$1.195B; SUBLOCADE net revenue: $905M–$945M, 8% growth at midpoint.
Adjusted EBITDA guidance: $535M–$575M, 30% growth at midpoint, with margin expansion to 48%.
Non-GAAP operating expenses expected at $430M–$450M; operating expenses capped at $450M.
SUBLOCADE dispense unit growth expected to accelerate from 7% in 2025 to mid-teens in 2026.
Cash flow from operations expected to reach ~$300M in 2026.
Latest events from Indivior
- SUBLOCADE drives strong revenue and EBITDA growth, with 2026 set for further acceleration.INDV
Investor presentation26 Feb 2026 - Q3 2024 revenue up 13% and profit up 62%, led by SUBLOCADE and strong U.S. sales.INDV
Q3 202416 Feb 2026 - Q1 2025 revenue fell 6% as generic competition intensified; cost controls supported profit.INDV
Q1 202516 Feb 2026 - FY 2024 guidance cut, PERSERIS discontinued, $85m litigation settled; long-term targets intact.INDV
Investor Update3 Feb 2026 - Q2 2024 revenue up 8%, SUBLOCADE up 24%, $75m litigation provision, $100m buyback.INDV
Q2 20243 Feb 2026 - Addiction treatment growth accelerates with new products, pipeline advances, and U.S. market focus.INDV
Jefferies Global Healthcare Conference31 Jan 2026 - OUD treatment growth continues amid easing Medicaid headwinds and focused pipeline development.INDV
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - 2024 SUBLOCADE guidance lowered amid competition, but long-term growth outlook remains strong.INDV
Guidance19 Jan 2026 - SUBLOCADE retains leadership in a growing LAI market, with strategic focus and operational streamlining.INDV
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026